WHITE PAPERS

Axiom Mid-Year Data Review 2022

In this report, Axiom provides a review on pivotal and paradigm shifting data from the first half of 2022 and offers our perspective on...

Insights on Cell Therapy From IO360

Executive Summary IO360 underscored the importance of the starting cell type, as the overall consensus of the superior cell type was the...

Oncology: Looking ahead

In this report, Axiom provides overview of key advances in 2021, and offer our perspective on emerging trends and their implications...

ESMO 2021 Highlights

Practice changing new data was presented at the ESMO Congress 2021. Take a look at the Axiom’s ESMO 2021 highlights.

Town Hall on ASCO 2021: Thoughts From the Think Tank

ASCO 2021 - Thoughts from the Think Tank. In this ASCO recap, we share our analysis on major updates in solid tumors including thoughts...

BREAST CANCER: A Year In Review

Highlights Results from monarchE (abemaciclib + ET) confirm the benefit of abemaciclib in in high risk, HR+ BC Although FDA ODAC voted...

ASCO 2020 Highlights

Any apprehension that COVID-19 would also disrupt the legacy of ASCO innovation, was ameliorated by a procession of breakthrough findings...

A Breakthrough in Understanding Tumor Origins

A global consortium of thousands of researchers published a groundbreaking oncology paper in Nature. They investigated the evolution of...

ESMO 2019 Meeting Highlights

ESMO 2019 featured a staggering 2,200 abstracts including 92 late breaking abstracts, befitting its standing as one of the largest...

Progress in Oncology: Highlights from ASCO 2019

The meeting provided a spectrum of practice-changing studies, early-stage data for novel therapies, and advances in notable trends such...

AXIOM
THINK TANK